IL17A and COVID-19: In the ongoing COVID-19 pandemic, damage to the mucosal barrier and immune cells due to the overproduction of pro-inflammatory (IL-1, IL-6, IL-12, IL-17, IFN-γ, TNFα) cytokines (cytokine storm) was evident in some COVID-19 patients [138].